We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Genetic Tools Improve Breast Cancer Risk Prediction for African American Women

By LabMedica International staff writers
Posted on 09 Feb 2026

Despite advances in genetic testing, breast cancer death rates remain disproportionately high among women of African ancestry. More...

Existing risk prediction tools often fail to accurately assess risk in this group, contributing to later diagnoses and poorer outcomes. Greater genetic diversity and higher rates of aggressive tumor subtypes further complicate early detection. Researchers have now developed improved genetic risk models that significantly enhance breast cancer risk prediction in women of African ancestry.

In the study led by the University of Chicago Medicine (Chicago, IL, USA) researchers used genetic data from more than 36,000 women to develop new polygenic risk score (PRS) models specifically for women of African ancestry. The models were built using data from the African Ancestry Breast Cancer Genetics Consortium, which includes participants from the U.S., the Caribbean, and Sub-Saharan Africa.

Polygenic risk scores estimate cancer risk by analyzing multiple single-nucleotide polymorphisms (SNPs) across the genome. Because African ancestry populations have greater genetic diversity, models trained primarily on European data often miss key risk signals. The researchers created separate PRS models for overall breast cancer, estrogen receptor–positive cancer, estrogen receptor–negative cancer, and triple-negative breast cancer, ensuring more precise risk stratification.

The new models showed significantly improved predictive performance, with area under the curve (AUC) values ranging from 0.61 to 0.64, compared with 0.56 to 0.58 for earlier models. The research, published in Nature Genetics, also demonstrated that simplified models using fewer genetic markers maintained similar accuracy. Validation across multiple independent datasets confirmed the robustness of the approach.

The findings suggest that women identified as high risk could benefit from earlier and more frequent screening, potentially starting in their early 30s. Combining PRS results with family history further strengthened risk prediction, identifying individuals with lifetime breast cancer risks exceeding 50%. Researchers emphasize that future work will refine these models for broader African populations and support more equitable cancer prevention strategies.

“With improved risk prediction, doctors can start screening earlier for women at higher risk, tailor care based on a woman’s specific risk profile and catch the cancers sooner,” said Professor Dezheng Huo, PhD, senior author of the study.

Related Links:
University of Chicago Medicine


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The study identified a distinct immune signature associated with treatment-resistant myasthenia gravis (Dodd, Katherine C. et al., Med (2026). DOI: 10.1016/j.medj.2025.100987)

Immune Signature Identified in Treatment-Resistant Myasthenia Gravis

Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.